title: Urate oxidase should remain mandatory in patients at high risk of tumor lysis syndrome.
authors.affiliation: Jean Monnet University, Saint Etienne, France.
authors.forename: Michael
authors.initials: M
authors.lastname: Darmon
authors.affiliation: Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarrez, France.
authors.forename: Aurelie
authors.initials: A
authors.lastname: Bourmaud
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Bobigny, France.
authors.forename: François
authors.initials: F
authors.lastname: Vincent
mesh_terms: D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015275:Tumor Lysis Syndrome / Q000188:drug therapy*; D014503:Urate Oxidase / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D014503:Urate Oxidase